A new Covid-19 vaccine developed in the US is almost 95 per cent effective at protecting against the virus, according to research.
Data from the firm Moderna reportedly followed a trial of around 30,000 people.
Half were given two doses of the vaccine, four weeks apart, while the rest had dummy injections.
Bosses of the US firm described their findings as 'great' news, and say the jab is 94.5 per cent effective at immunising against coronavirus.
They plan to apply for approval to use the vaccine in the next few weeks, the BBC reports.
Tal Zaks, the chief medical officer at Moderna, said: The overall effectiveness has been remarkable... it's a great day."
It has been stressed the vaccine is still in the early stages of development, and rollout is not expected to be imminent.
Moderna's analysis was based on the first 95 to develop Covid-19 symptoms.
It has been reported just five of these cases were people who had been given the vaccine - and the remaining 90 had been given the placebo.
